adairАллергология и Иммунология в ПедиатрииAllergology and Immunology in Paediatrics2500-11752712-7958Ассоциация детских аллергологов и иммунологов России10.24412/2500-1175-2021-1-15-23adair-4Research ArticleСтатьиИзменение реактивности базофилов и синтеза специфических иммуноглобулинов Е под влиянием аллерген-иммунотерапииChanges in basophil reactivity and synthesis of specific immunoglobulins E influenced by allergen-immunotherapyhttps://orcid.org/0000-0002-4069-0566БарычеваЛ. Ю.BarychevaL. Yu.

Барычева Людмила Юрьевна, доктор медицинских наук, профессор, заведующий кафедрой иммунологии с курсом ДПО Ставропольского государственного медицинского университета МЗ России

355017, г. Ставрополь, ул. Мира, д. 310

Liudmila Yu. Barycheva, MD, Professor, Head of the Department of Immunology with a course of continuing professional education at Stavropol State Medical University

310 Mira street, 355017, Stavropol, Russia

for_ludmila@inbox.ruДушинаЛ. В.DushinaL. V.

г. Ставрополь

Stavropol

МедведенкоЮ. Н.MedvedenkoYu. N.

г. Ставрополь

Stavropol

ФГБО ВО «Ставропольский государственный медицинский университет» Министерства Здравоохранения Российской Федерации; АНМО «Ставропольский краевой клинический консультативно-диагностический центр»Federal State Budgetary Institution for Higher Education Stavropol State Medical University of the Ministry of Health Russian Federation; Stavropol Regional Clinical&Counseling Diagnostics CenterФГБО ВО «Ставропольский государственный медицинский университет» Министерства Здравоохранения Российской ФедерацииFederal State Budgetary Institution for Higher Education Stavropol State Medical University of the Ministry of Health Russian Federation202120032023011523Copyright © Барычева Л.Ю., Душина Л.В., Медведенко Ю.Н., 20232023Барычева Л.Ю., Душина Л.В., Медведенко Ю.Н.Barycheva L.Y., Dushina L.V., Medvedenko Y.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://adair.elpub.ru/jour/article/view/4

Проведено исследование теста спонтанной и индуцированной аллергеном активации базофилов (BAT) и показателей специфических IgE к мажорным аллергенам пыльцы трав на фоне аллерген-иммунотерапии (АИТ) у пациентов, сенсибилизированных к пыльце сорняков. Установлено, что показатели специфических IgE к мажорным аллергенам амброзии (nAmb a 1) и полыни (nArt v 1), а также коэффициенты IgE спец. nAmb a 1/IgE общ. и IgE спец. nArt v 1/IgE общ. не изменились после 2-х курсов предсезонной АИТ. Выявлено уменьшение показателей BAT под влиянием АИТ. Показано, что раннее снижение индекса стимуляции BAT (ИС BAT) чаще наблюдается у пациентов с положительными результатами лечения.

The study focused on spontaneous and allergen-induced basophil activation (BAT) as well as on specific IgE indicators to major meadow grass pollen allergens on the background of allergen-immunotherapy (AIT) in patients sensitized to weed pollen. The study revealed that the specific IgE indicators to major ragweed allergens (nAmb a 1) and wormwood (nArt v 1) allergens, as well as the ratios of spec. IgE nAmb a 1/gen. IgE, and spec. IgE nArt v 1/gen. IgE do not change after 2 courses of pre-seasonal ASIT. There was a decrease detected in BAT indicators under the effect of ASIT. An early decrease in the BAT stimulation index (BAT IC) was shown to be more common for patients with positive treatment outcomes.

поллинозаллерген-иммунотерапияспецифический IgEреактивность базофиловpollinosisallergen-immunotherapyspecific IgEbasophil reactivityReferencesTraidl-Hoffmann C. Allergy — an environmental disease. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz. 2017; 60(6): 584–591. doi:10.1007/s00103-017-2547-4.Traidl-Hoffmann C. Allergy — an environmental disease. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz. 2017; 60(6): 584–591. doi:10.1007/s00103-017-2547-4.Porteous T., Wyke S., Smith S. [et al.] «Help for Hay fever», a goal — focused intervention for people with intermittent allergic rhinitis, delivered in Scottish community pharmacies: study protocol a pilot cluster randomized controlled trial. Trials. 2013; 15(14): 217. doi:10.1186/1745-6215-14-217.Porteous T., Wyke S., Smith S. [et al.] «Help for Hay fever», a goal — focused intervention for people with intermittent allergic rhinitis, delivered in Scottish community pharmacies: study protocol a pilot cluster randomized controlled trial. Trials. 2013; 15(14): 217. doi:10.1186/1745-6215-14-217.Damialis A., Traidl-Hoffmann C., Treudler R. Climate Change and Pollen Allergies. Biodiversity and Health in the Face of Climate Change. Springer, Cham. 2019. doi:10.1007/978-3-030-02318-83.Damialis A., Traidl-Hoffmann C., Treudler R. Climate Change and Pollen Allergies. Biodiversity and Health in the Face of Climate Change. Springer, Cham. 2019. doi:10.1007/978-3-030-02318-83.Bergmann K.C., Heinrich J., Niemann H. Current status of allergy prevalence in Germany: position paper of the environmental medicine commission of the Robert Koch institute. Allergo J. Int. 2016; 25:6–10. doi:10.1007/s40629-016-0092-6.Bergmann K.C., Heinrich J., Niemann H. Current status of allergy prevalence in Germany: position paper of the environmental medicine commission of the Robert Koch institute. Allergo J. Int. 2016; 25:6–10. doi:10.1007/s40629-016-0092-6.Аллергология и клиническая иммунология. Клинические рекомендации / Под ред. Р.М. Хаитова, Н.И. Ильиной. Москва: ГЭОТАР — Медиа, 2019.Allergologiya i klinicheskaya immunologiya. Klinicheskie rekomendatsii / Pod red. R.M. Khaitova, N.I. Il'inoy. Moskva: GEOTAR — Media, 2019. (In Russ.).Трофименко С.Л., Ракова К.А. Заболеваемость поллинозом в Ростове-на-Дону. Российская ринология. 2015; 23: 36–39. doi: 10.17116/rosrino201523136-39Trofimenko S.L., Rakova K.A. Pollen allergy in Rostov-on-Don. — Rossiiskaya Rinologiya. 2015; 23: 36–39. (In Russ.). doi: 10.17116/rosrino201523136-39Мачарадзе Д.Ш. Амброзийная аллергия. Особенности диагностики и лечения. Медицинский оппонент 2019; 2(6): 48–55.Macharadze D.Sh. Ambrosia allergy. Features of diagnosis and treatment. — Meditsinskiy opponent. 2019; 2(6): 48–55. (In Russ.).Pfaar O., Bonini S., Cardona V. [et al.]. Perspectives in allergen immunotherapy: 2017 and beyond. Allergy. 2018;73(104): 5–23. doi:10.1111/all.13355Pfaar O., Bonini S., Cardona V. [et al.]. Perspectives in allergen immunotherapy: 2017 and beyond. Allergy. 2018;73(104): 5–23. doi:10.1111/all.13355Масальский С.С., Смолкин Ю.С. Антигистаминные препараты в терапии аллергического ринита. Аллергология и иммунология в педиатрии. 2018; 2(53): 5–13. doi:10.24411/2500-1175-2018-00006.Masalskiy S.S., Smolkin Y.S. Antihistamines in the treatment of allergic rhinitis. — Allergologiya i immunologiya v pediatrii. 2018; 2(53): 5–13. (In Russ.). doi:10.24411/2500-1175-2018-00006.Балаболкин И.И. Поллиноз у детей и подростков: современные аспекты патогенеза и тенденции в терапии. Аллергология и иммунология в педиатрии. 2020; 62 (3): 6–14. doi: 10.24411/2500-1175-2020-10007Balabolkin I.I. Pollinosis in children and adolescents: modern aspects of pathogenesis and tendencies in therapy. — Allergologiya i immunologiya v pediatrii. 2020; 62 (3): 6–14. (In Russ.). doi: 10.24411/2500-1175-2020-10007Sindher S.B., Long A., Acharya S. The Use of Biomarkers to Predict Aero-Allergen and Food Immunotherapy Responses. Clin. Rev. Allergy Immunol. 2018; 55(2): 190–204. doi:10.1007/s12016-018-8678-z.Sindher S.B., Long A., Acharya S. The Use of Biomarkers to Predict Aero-Allergen and Food Immunotherapy Responses. Clin. Rev. Allergy Immunol. 2018; 55(2): 190–204. doi:10.1007/s12016-018-8678-z.Lam H.Y. Tergaonkar V., Ahn K.S. Mechanisms of allergen-specific immunotherapy for allergic rhinitis and food allergies. Biosci Rep. 2020; 40(4). BSR20200256. doi:10.1042/BSR20200256.Lam H.Y. Tergaonkar V., Ahn K.S. Mechanisms of allergen-specific immunotherapy for allergic rhinitis and food allergies. Biosci Rep. 2020; 40(4). BSR20200256. doi:10.1042/BSR20200256.Sindher S.B., Long A., Acharya S. [et al.] The Use of Biomarkers to Predict Aero-Allergen and Food Immunotherapy Responses. Clin. Rev. Allergy Immunol. 2018; 55(2): 190–204. doi:10.1007/s12016-0188678-z.Sindher S.B., Long A., Acharya S. [et al.] The Use of Biomarkers to Predict Aero-Allergen and Food Immunotherapy Responses. Clin. Rev. Allergy Immunol. 2018; 55(2): 190–204. doi:10.1007/s12016-0188678-z.Moingeon P. Biomarkers for Allergen Immunotherapy: A "Panoromic" View. Immunol. Allergy Clin. North Am. 2016; 36(1): 161–179. doi:10.1016/j.iac.2015.08.004.Moingeon P. Biomarkers for Allergen Immunotherapy: A "Panoromic" View. Immunol. Allergy Clin. North Am. 2016; 36(1): 161–179. doi:10.1016/j.iac.2015.08.004.Hamilton R.G. Microarray Technology applied to human allergic disease. Microarrays (Basel). 2017; 6(1): 3. doi: 10.3390/microarrays6010003.Hamilton R.G. Microarray Technology applied to human allergic disease. Microarrays (Basel). 2017; 6(1): 3. doi: 10.3390/microarrays6010003.Callery E.L., Keymer С., Barnes N.A., Rowbottom A.W. Component-resolved diagnostics in the clinical and laboratory investigation of allergy. Ann. Clin. Biochem. 2020; 57(1): 26–35. doi: 10.1177/0004563219877434.Callery E.L., Keymer С., Barnes N.A., Rowbottom A.W. Component-resolved diagnostics in the clinical and laboratory investigation of allergy. Ann. Clin. Biochem. 2020; 57(1): 26–35. doi: 10.1177/0004563219877434.Feng M., Zeng X., Su Q. Allergen Immunotherapy-Induced Immunoglobulin G4 Reduces Basophil Activation in House Dust Mite-Allergic Asthma Patients. J. Front. Cell Dev. Biol. 2020; 8: 30. doi: 10.3389/fcell.2020.00030.Feng M., Zeng X., Su Q. Allergen Immunotherapy-Induced Immunoglobulin G4 Reduces Basophil Activation in House Dust Mite-Allergic Asthma Patients. J. Front. Cell Dev. Biol. 2020; 8: 30. doi: 10.3389/fcell.2020.00030.Shamji, M.H., Durham S.R. Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers. J. Allergy Clin. Immunol. 2017; 140(6): P. 1485–1498. doi:10.1016/j.jaci.2017.10.010.Shamji, M.H., Durham S.R. Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers. J. Allergy Clin. Immunol. 2017; 140(6): P. 1485–1498. doi:10.1016/j.jaci.2017.10.010.Pfaar O., Demoly P., Gerth van Wijk R. [et al.]. European Academy of Allergy and Clinical Immunology. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy. 2014; 69(7):854–867. doi: 10.1111/all.12383.Pfaar O., Demoly P., Gerth van Wijk R. [et al.]. European Academy of Allergy and Clinical Immunology. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy. 2014; 69(7):854–867. doi: 10.1111/all.12383.Адо А.Д. Частная аллергология. М.: Медицина, 1976. 510 c.Ado A.D. Chastnaya allergologiya. M.: Meditsina, 1976. 510 c. (In Russ.).Chen J., Zhou Y., Wang Y. [et al.] Specific immunoglobulin E and immunoglobulin G4 toward major allergens of house-dust mite during allergen-specific immunotherapy. Am. J. Rhinol. Allergy. 2017; 31(3): 156–160. doi: 10.2500/ajra.2017.31.4434.Chen J., Zhou Y., Wang Y. [et al.] Specific immunoglobulin E and immunoglobulin G4 toward major allergens of house-dust mite during allergen-specific immunotherapy. Am. J. Rhinol. Allergy. 2017; 31(3): 156–160. doi: 10.2500/ajra.2017.31.4434.Sahin E., Bafaqeeh S.A., Guven S.G. [et al.]. Mechanism of action of allergen immunotherapy. Am. J. Rhinol. Allergy. 2016; 30(5): 1–3. doi:10.2500/ajra.2016.30.4367.Sahin E., Bafaqeeh S.A., Guven S.G. [et al.]. Mechanism of action of allergen immunotherapy. Am. J. Rhinol. Allergy. 2016; 30(5): 1–3. doi:10.2500/ajra.2016.30.4367.Narisety S.D., Frischmeyer-Guerrerio P.A., Keet C.A. [et al.]. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy. J. Allergy Clin. Immunol. 2015; 135(5): 1275–1282. doi:10.1016/j.jaci.2014.11.005.Narisety S.D., Frischmeyer-Guerrerio P.A., Keet C.A. [et al.]. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy. J. Allergy Clin. Immunol. 2015; 135(5): 1275–1282. doi:10.1016/j.jaci.2014.11.005.Vickery B.P., Scurlock A.M., Kulis M. [et al.]. Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy. J. Allergy Clin. Immunol. 2014; 133(2): 468–475. doi: 10.1016/j.jaci.2013.11.007.Vickery B.P., Scurlock A.M., Kulis M. [et al.]. Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy. J. Allergy Clin. Immunol. 2014; 133(2): 468–475. doi: 10.1016/j.jaci.2013.11.007.Gorelik M., Narisety S.D., Guerrerio A.L. [et al.]. Suppression of the immunologic response to peanut during immunotherapy is often transient. J. Allergy Clin. Immunol. 2015; 135(5): 1283–1292. doi: 10.1016/j.jaci.2014.11.010.Gorelik M., Narisety S.D., Guerrerio A.L. [et al.]. Suppression of the immunologic response to peanut during immunotherapy is often transient. J. Allergy Clin. Immunol. 2015; 135(5): 1283–1292. doi: 10.1016/j.jaci.2014.11.010.Zidarn M., Kosnik M., Silar M. [et al.]. Sustained effect of grass pollen subcutaneous immunotherapy on suppression of allergen-specific basophil response; a real-life, nonrandomized controlled study. Allergy. 2015; 70: 547–555. doi:10.1111/all.12581.Zidarn M., Kosnik M., Silar M. [et al.]. Sustained effect of grass pollen subcutaneous immunotherapy on suppression of allergen-specific basophil response; a real-life, nonrandomized controlled study. Allergy. 2015; 70: 547–555. doi:10.1111/all.12581.Liм Q., Li M., Yue W. [et al.]. Predictive factors for clinical response to allergy immunotherapy in children with asthma and rhinitis. Int. Arch. Allergy Immunol. 2014; 164(3): 210–217. doi:10.1159/000365630.Liм Q., Li M., Yue W. [et al.]. Predictive factors for clinical response to allergy immunotherapy in children with asthma and rhinitis. Int. Arch. Allergy Immunol. 2014; 164(3): 210–217. doi:10.1159/000365630.Andorf S., Borres M.P., Block W. [et al.]. Association of Clinical Reactivity with Sensitization to Allergen Components in Multifood-Allergic Children. J Allergy Clin Immunol Pract. 2017; 5(5): 1325–1334. doi:10.1016/j.jaip.2017.01.016.Andorf S., Borres M.P., Block W. [et al.]. Association of Clinical Reactivity with Sensitization to Allergen Components in Multifood-Allergic Children. J Allergy Clin Immunol Pract. 2017; 5(5): 1325–1334. doi:10.1016/j.jaip.2017.01.016.Bidad K., Nawijn M.C., Van Oosterhout A.J. [et al.]. Basophil activation test in the diagnosis and monitoring of mastocytosis patients with wasp venom allergy on immunotherapy. Cytometry B Clin. Cytom. 2014; 86(3): 183–190. doi:10.1002/cyto.b.21148.Bidad K., Nawijn M.C., Van Oosterhout A.J. [et al.]. Basophil activation test in the diagnosis and monitoring of mastocytosis patients with wasp venom allergy on immunotherapy. Cytometry B Clin. Cytom. 2014; 86(3): 183–190. doi:10.1002/cyto.b.21148.Ozdemir S.K., Sin B.A., Guloglu D. [et al.]. Short-term preseasonal immunotherapy: is early clinical efficacy related to the basophil response? Int. Arch. Allergy Immunol. 2014; 164(3): 237–245. doi: 10.1159/000365628.Ozdemir S.K., Sin B.A., Guloglu D. [et al.]. Short-term preseasonal immunotherapy: is early clinical efficacy related to the basophil response? Int. Arch. Allergy Immunol. 2014; 164(3): 237–245. doi: 10.1159/000365628.Sainte-Laudy J. Touraine F., Cluzan D., Belle Moudourou F. Follow-Up of Venom Immunotherapy on Flow Cytometry and Definition of a Protective Index. Int. Arch. Allergy Immunol. 2016; 170(4): 243–250. doi:10.1159/000449162.Sainte-Laudy J. Touraine F., Cluzan D., Belle Moudourou F. Follow-Up of Venom Immunotherapy on Flow Cytometry and Definition of a Protective Index. Int. Arch. Allergy Immunol. 2016; 170(4): 243–250. doi:10.1159/000449162.Plewako H., Wosinska K., Arvidsson M. [et al.]. Basophil interleukin 4 and interleukin 13 production is suppressed during the early phase of rush immunotherapy. Int. Arch. Allergy Immunol. 2006; 141(4): 346–353. doi: 10.1159/000095461.Plewako H., Wosinska K., Arvidsson M. [et al.]. Basophil interleukin 4 and interleukin 13 production is suppressed during the early phase of rush immunotherapy. Int. Arch. Allergy Immunol. 2006; 141(4): 346–353. doi: 10.1159/000095461.Gokmen N.M. Ersoy R.O., Gulbahar O. [et al.]. Desensitization effect of preseasonal seven-injection allergoid immunotherapy with olive pollen on basophil activation: the efficacy of olive pollen-specific preseasonal allergoid immunotherapy on basophils. Int. Arch. Allergy Immunol. 2012; 159: 75–82. doi:10.1159/000335251.Gokmen N.M. Ersoy R.O., Gulbahar O. [et al.]. Desensitization effect of preseasonal seven-injection allergoid immunotherapy with olive pollen on basophil activation: the efficacy of olive pollen-specific preseasonal allergoid immunotherapy on basophils. Int. Arch. Allergy Immunol. 2012; 159: 75–82. doi:10.1159/000335251.Schmid J.M., Würtzen P.A., Dahl R., Hoffmann H.J. Early improvement in basophil sensitivity predicts symptom relief with grass pollen immunotherapy. J Allergy Clin Immunol. 2014;134: 741–744.Schmid J.M., Würtzen P.A., Dahl R., Hoffmann H.J. Early improvement in basophil sensitivity predicts symptom relief with grass pollen immunotherapy. J Allergy Clin Immunol. 2014;134: 741–744.Van Overtvelt L., Baron-Bodo V., Horiot S. [et al.]. Changes in basophil activation during grass-pollen sublingual immunotherapy do not correlate with clinical efficacy. Allergy. 2011; 66(12): 1530–1537. doi:10.1111/j.1398-9995.2011.02696.x.Van Overtvelt L., Baron-Bodo V., Horiot S. [et al.]. Changes in basophil activation during grass-pollen sublingual immunotherapy do not correlate with clinical efficacy. Allergy. 2011; 66(12): 1530–1537. doi:10.1111/j.1398-9995.2011.02696.x.Czarnobilska E.M., Bulanda M., Śpiewak R. The usefulness of the basophil activation test in monitoring specific immunotherapy with house dust mite allergens. Postepy Dermatol. Alergol. 2018; 35(1): 93–98. doi:10.5114/ada.2018.73169.Czarnobilska E.M., Bulanda M., Śpiewak R. The usefulness of the basophil activation test in monitoring specific immunotherapy with house dust mite allergens. Postepy Dermatol. Alergol. 2018; 35(1): 93–98. doi:10.5114/ada.2018.73169.Kim S.H., Kim S.H., Chung S.J. [et al.]. Changes in basophil activation during immunotherapy with house dust mite and mugwort in patients with allergic rhinitis. Asia Pac. Allergy. 2018; 8(1): 6. doi:10.5415/apallergy.2018.8.e6.Kim S.H., Kim S.H., Chung S.J. [et al.]. Changes in basophil activation during immunotherapy with house dust mite and mugwort in patients with allergic rhinitis. Asia Pac. Allergy. 2018; 8(1): 6. doi:10.5415/apallergy.2018.8.e6.Rodríguez Trabado A., Cámara Hijón C., Ramos Cantariño A. [et al.]. Short-, Intermediate-, and Long-Term Changes in Basophil Reactivity Induced by Venom Immunotherapy. Allergy Asthma Immunol. Res. 2016; 8(5): 412–420. doi:10.4168/aair.2016.8.5.412.Rodríguez Trabado A., Cámara Hijón C., Ramos Cantariño A. [et al.]. Short-, Intermediate-, and Long-Term Changes in Basophil Reactivity Induced by Venom Immunotherapy. Allergy Asthma Immunol. Res. 2016; 8(5): 412–420. doi:10.4168/aair.2016.8.5.412.Witting Christensen S.K., Kortekaas Krohn I., Thuraiaiyah J. [et al.]. Sequential allergen desensitization of basophils is non-specific and may involve p38 MAPK. Allergy. 2014; 69(10): 1343–1349. doi:10.1111/all.12482.Witting Christensen S.K., Kortekaas Krohn I., Thuraiaiyah J. [et al.]. Sequential allergen desensitization of basophils is non-specific and may involve p38 MAPK. Allergy. 2014; 69(10): 1343–1349. doi:10.1111/all.12482.Keet C.A., Frischmeyer-Guerrerio P.A., Thyagarajan A. [et al.]. The safety and efficacy of sublingual and oral immunotherapy for milk allergy. J. Allergy Clin. Immunol. 2012; 129(2): 448–455. doi: 10.1016/j.jaci.2011.10.023.Keet C.A., Frischmeyer-Guerrerio P.A., Thyagarajan A. [et al.]. The safety and efficacy of sublingual and oral immunotherapy for milk allergy. J. Allergy Clin. Immunol. 2012; 129(2): 448–455. doi: 10.1016/j.jaci.2011.10.023.Thyagarajan A., Jones S.M., Calatroni A. [et al.]. Evidence of pathway-specific basophil anergy induced by peanut oral immunotherapy in peanut-allergic children. Clin. Exp. Allergy. 2012; 42(8): 1197–1205. doi:10.1111/j.1365-2222.2012.04028.x.Thyagarajan A., Jones S.M., Calatroni A. [et al.]. Evidence of pathway-specific basophil anergy induced by peanut oral immunotherapy in peanut-allergic children. Clin. Exp. Allergy. 2012; 42(8): 1197–1205. doi:10.1111/j.1365-2222.2012.04028.x.MacGlashan, D.W. Syk expression and IgE-mediated histamine release in basophils as biomarkers for predicting the clinical efficacy of omalizumab. J. Allergy Clin. Immunol. 2017; 139(5): 1680–1682. doi:10.1016/j.jaci.2016.12.965.MacGlashan, D.W. Syk expression and IgE-mediated histamine release in basophils as biomarkers for predicting the clinical efficacy of omalizumab. J. Allergy Clin. Immunol. 2017; 139(5): 1680–1682. doi:10.1016/j.jaci.2016.12.965.

The authors declare that there are no conflicts of interest present.